Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
The Oncologist
|
December 26, 2024
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer
Camille Mehlman, Aurelie Swalduz, Isabelle Monnet, et al.
Emerging Infectious Diseases
|
October 24, 2024
Mpox Hepatic and Pulmonary Lesions in HIV/Hepatitis B Virus Co-Infected Patient, France
Ruxandra Calin, Claire Périllaud-Dubois, Stéphane Marot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry
Arianna Marinello, Julia K Rotow, Meghanne Lomibao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 23, 2021
Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study
Marion Panhaleux, Olivier Espitia, Benjamin Terrier, et al.
Frontiers in Immunology
|
January 6, 2023
Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells
Marianne Gazzano, Christophe Parizot, Dimitri Psimaras, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 1, 2024
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort
Aurélie Swalduz, Michèle Beau-Faller, David Planchard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 22, 2023
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS<sup>G12C</sup>-Mutant Lung Cancer
Ali Chour, Julie Denis, Céline Mascaux, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 9, 2025
Human Immunodeficiency Virus Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in NSCLC
Baptiste Abbar, Karim Labreche, Jacques Cadranel, et al.
The European Respiratory Journal
|
November 13, 2025
European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer
Alessandro Brunelli, Georgia Hardavella, Rudolf M Huber, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
November 13, 2025
European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer
Alessandro Brunelli, Georgia Hardavella, Rudolf M Huber, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
The Oncologist
|
December 26, 2024
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancer
Camille Mehlman, Aurelie Swalduz, Isabelle Monnet, et al.
Emerging Infectious Diseases
|
October 24, 2024
Mpox Hepatic and Pulmonary Lesions in HIV/Hepatitis B Virus Co-Infected Patient, France
Ruxandra Calin, Claire Périllaud-Dubois, Stéphane Marot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib - Results from the RET-MAP Registry
Arianna Marinello, Julia K Rotow, Meghanne Lomibao, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 23, 2021
Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study
Marion Panhaleux, Olivier Espitia, Benjamin Terrier, et al.
Frontiers in Immunology
|
January 6, 2023
Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells
Marianne Gazzano, Christophe Parizot, Dimitri Psimaras, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 1, 2024
Real-world efficacy of the dabrafenib-trametinib (D-T) combination in BRAF V600E-mutated metastatic non-small cell lung cancer (NSCLC): Results from the IFCT-2004 BLaDE cohort
Aurélie Swalduz, Michèle Beau-Faller, David Planchard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 22, 2023
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS<sup>G12C</sup>-Mutant Lung Cancer
Ali Chour, Julie Denis, Céline Mascaux, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 9, 2025
Human Immunodeficiency Virus Impairs Immune Responses to Tumor Neoepitopes Without Altering Mutational Profiles in NSCLC
Baptiste Abbar, Karim Labreche, Jacques Cadranel, et al.
The European Respiratory Journal
|
November 13, 2025
European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer
Alessandro Brunelli, Georgia Hardavella, Rudolf M Huber, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
November 13, 2025
European Respiratory Society and European Society of Thoracic Surgeons clinical practice guideline on fitness for curative intent treatment of lung cancer
Alessandro Brunelli, Georgia Hardavella, Rudolf M Huber, et al.
Page
of 6